Flying On Two Wings: Ypsomed's Dual-Engine Strategy For Success In China

China’s pharmaceutical industry is rapidly transforming from a domestic market powerhouse into a global force in drug development, with Chinese biopharma companies contributing a growing share of new molecules entering clinical trials. As pipelines expand across biologics, diabetes, oncology, autoimmune diseases and other injectable therapies, drug developers face increasing pressure to balance speed, scalability and global regulatory expectations.

Success in this evolving landscape depends on more than selecting a delivery device. Pharmaceutical companies increasingly require partners that combine local manufacturing capabilities, regulatory expertise, supply chain reliability and global quality standards. With injectable therapies driving demand for self-injection technologies, integrated development and production models are becoming critical for supporting both domestic growth and international commercialization strategies.

Explore how China’s injectable market is evolving, the challenges facing pharmaceutical companies operating in this dynamic environment, and why local presence paired with global expertise is emerging as a key factor in bringing innovative therapies to patients efficiently and at scale.